ChiCTR2400085710 版本V1.0 版本创建时间2024/06/17 15:29:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400085710 

最近更新日期:

Date of Last Refreshed on:

2024-06-17 15:29:44 

注册时间:

Date of Registration:

2024-06-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

玉树藏族自治州人群幽门螺杆菌感染危险因素分析和内镜结果的关系及内镜治疗情况的研究

Public title:

Analysis of risk factors for Helicobacter pylori infection in Yushu Tibetan Autonomous Prefecture and the relationship between endoscopic results and endoscopic treatment

注册题目简写:

English Acronym:

研究课题的正式科学名称:

玉树藏族自治州人群幽门螺杆菌感染危险因素分析和内镜结果的关系及内镜治疗情况的研究

Scientific title:

Analysis of risk factors for Helicobacter pylori infection in Yushu Tibetan Autonomous Prefecture and the relationship between endoscopic results and endoscopic treatment

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张秋梅 

研究负责人:

宾楚轩 

Applicant:

Zhang Qiumei 

Study leader:

Bin Chuxuan 

申请注册联系人电话:

Applicant telephone:

+86 136 9921 2303

研究负责人电话:

Study leader's telephone:

+86 136 9921 2303

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

binchuxuan@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

binchuxuan@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

青海省玉树藏族自治州扎西大通北巷4号

研究负责人通讯地址:

青海省玉树藏族自治州扎西大通北巷4号

Applicant address:

No. 4, Tashi Datong North Lane, Yushu Tibetan Autonomous Prefecture, Qinghai Province

Study leader's address:

No. 4, Tashi Datong North Lane, Yushu Tibetan Autonomous Prefecture, Qinghai Province

申请注册联系人邮政编码:

Applicant postcode:

815099

研究负责人邮政编码:

Study leader's postcode:

815099

申请人所在单位:

青海省玉树藏族自治州人民医院

Applicant's institution:

People's Hospital of Yushu Tibetan Autonomous Prefecture, Qinghai Province

研究负责人所在单位:

青海省玉树藏族自治州人民医院

Affiliation of the Leader:

People's Hospital of Yushu Tibetan Autonomous Prefecture, Qinghai Province

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

yszhp-xhnk-2024-04

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

玉树州人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Yushu Prefecture People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-17 00:00:00

伦理委员会联系人:

苗文星

Contact Name of the ethic committee:

Miao Wenxing

伦理委员会联系地址:

青海省玉树藏族自治州扎西大通北巷4号

Contact Address of the ethic committee:

No. 4, Tashi Datong North Lane, Yushu Tibetan Autonomous Prefecture, Qinghai Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 155 0976 1844

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

玉树藏族自治州人民医院

Primary sponsor:

Yushu Tibetan Autonomous Prefecture People's Hospital

研究实施负责(组长)单位地址:

青海省玉树藏族自治州扎西大通北巷4号

Primary sponsor's address:

No. 4, Tashi Datong North Lane, Yushu Tibetan Autonomous Prefecture, Qinghai Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

青海

市(区县):

Country:

China

Province:

Qinghai

City:

单位(医院):

玉树州藏族自治州人民医院

具体地址:

青海省玉树藏族自治州扎西大通北巷4号

Institution
hospital:

Yushu Tibetan Autonomous Prefecture People's Hospital

Address:

No. 4, Tashi Datong North Lane, Yushu Tibetan Autonomous Prefecture, Qinghai Province

经费或物资来源:

Source(s) of funding:

none

Target disease:

Helicobacter pylori infection

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

主要研究目的:调查玉树地区幽门螺杆菌的发病率和危险因素 次要研究目的:评估主要流行的幽门螺杆菌类型、与胃镜结果的相关性和上消化道疾病内镜治疗情况  

Objectives of Study:

Main objective: To investigate the incidence and risk factors of Helicobacter pylori in Yushu area Secondary objectives: To evaluate the predominant prevalent H. pylori types, correlation with gastroscopy results, and endoscopic treatment of upper gastrointestinal disease

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)自2024年6月20日至2034年6月19日就诊于玉树藏族自治州人民医院并完善13C尿素呼气试验或完成胃镜检查的患者; 2)开展流行病学调查时采用13C尿素呼气试验、血清抗H.p抗体、粪便H.p抗原的患者。 3)签署知情同意书并愿意接受随访。

Inclusion criteria

1) Patients who have been admitted to Yushu Tibetan Autonomous Prefecture People's Hospital from June 20, 2024 to June 19, 2034 and have completed the 13C urea breath test or completed the gastroscopy; 2) Patients with 13C urea breath test, serum anti-H.p antibody, and fecal H.p antigen during epidemiological investigation. 3) Signed informed consent and willing to undergo follow-up.

排除标准:

1)拒绝签署知情同意书; 2)失访。

Exclusion criteria:

1) refusal to sign informed consent; 2) Loss to follow-up.

研究实施时间:

Study execute time:

From 2024-06-20 00:00:00 To 2034-06-19 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-20 00:00:00 To 2034-06-19 00:00:00  

干预措施:

Interventions:

组别:

幽门螺杆菌阳性患者

样本量:

231

Group:

Helicobacter pylori positive patients

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

幽门螺杆菌阴性患者

样本量:

231

Group:

Helicobacter pylori negative patients

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

青海省 

市(区县):

 

Country:

China 

Province:

Qinghai Province 

City:

 

单位(医院):

玉树藏族自治州人民医院 

单位级别:

二甲 

Institution
hospital:

People's Hospital of Yushu Tibetan Autonomous Prefecture, Qinghai Province

Level of the institution:

Secondary A

测量指标:

Outcomes:

指标中文名:

C13阳性患者

指标类型:

主要指标

Outcome:

C13 positive patients

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性胃炎的比例

指标类型:

次要指标

Outcome:

The proportion of chronic gastritis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病理结果

指标类型:

次要指标

Outcome:

Pathological results

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

C13呼气

组织:

Sample Name:

C13 expiratory

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

消化道粘膜

组织:

Sample Name:

gastrointestinal mucosa

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 120 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-06-17 15:29:44